Crossmark

Clinical burden of illness in patients with phenylketonuria (PKU) and associated comorbidities - a retrospective study of German health insurance claims data

Crossref DOI link: https://doi.org/10.1186/s13023-019-1153-y

Published Online: 2019-07-22

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Trefz, K. F.

Muntau, A. C.

Kohlscheen, K. M.

Altevers, J.

Jacob, C.

Braun, S.

Greiner, W.

Jha, A.

Jain, M.

Alvarez, I.

Lane, P.

Schröder, C.

Rutsch, F.
License Information

Text and Data Mining valid from 2019-07-22

Version of Record valid from 2019-07-22
More Information

Article History

Received: 28 March 2019

Accepted: 3 July 2019

First Online: 22 July 2019

Ethics approval and consent to participate

: This study used anonymized German claims data. Therefore, no ethics approval was needed by an independent ethics committee or institutional review board.The utilized database addresses all data protection regulations in Germany. To ensure the protection of individual data and privacy, regions that are smaller than federal states or patient cohorts with less than 100 individuals were not analyzed in a granular way. Furthermore, patient counts below 5 were reported as “< 5”.

: Not applicable.

: IA, MJ, AJ, PL, and CS are full-time employees and stockholders of BioMarin Europe Ltd. KK, JA, CJ, and SB are full-time employees of Xcenda, acting as contractors of BioMarin Europe Ltd. for the execution of this study. FT received honoraria for presentations from BioMarin. AM has been a member of scientific advisory boards supported by BioMarin Europe Ltd. and has received honoraria as a speaker for BioMarin Europe Ltd. FR has received speaker and consulting honoraria from BioMarin Europe Ltd.

Document is current

Any future updates will be listed below